Journal
Blood Advances
Publication Date
2-27-2024
Volume
8
Issue
4
First Page
1042
Last Page
1050
Document Type
Open Access Publication
DOI
10.1182/bloodadvances.2023011489
Rights and Permissions
Jain MD, Jacobs MT, Gao F, Nastoupil LJ, Spiegel JY, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Sehgal AR, Goy A, Hill BT, Andreadis C, Munoz J, Chavez JC, Bennani NN, Rapoport AP, Vose JM, Miklos D, Neelapu SS, Locke FL, Ghobadi A. Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium. Blood Adv. 2024 Feb 27;8(4):1042-1050. doi: 10.1182/bloodadvances.2023011489. © 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Recommended Citation
Jain, Michael D; Jacobs, Miriam T; Gao, Feng; Ghobadi, Armin; and et al., "Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: Results from the US Lymphoma CAR-T Consortium." Blood Advances. 8, 4. 1042 - 1050. (2024).
https://digitalcommons.wustl.edu/oa_4/3414
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
